(Q37842324)

24 August 2017

1 reference

title

Antibody-enzyme fusion proteins for cancer therapy (English)

1 reference

24 August 2017

1 reference

Carima Andrady

1

1 reference

24 August 2017

Surinder K Sharma

series ordinal

2

1 reference

24 August 2017

Kerry A Chester

series ordinal

3

1 reference

24 August 2017

publication date

1 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

3

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

193-211

1 reference

Antibody directed enzymes revive anti-cancer prodrugs concept

24 August 2017

cites work

1 reference

A cytotoxic agent can be generated selectively at cancer sites

21 January 2018

1 reference

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate

21 January 2018

1 reference

Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

21 January 2018

1 reference

Targeting: the ADEPT story so far.

21 January 2018

1 reference

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates

21 January 2018

1 reference

A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy

21 January 2018

1 reference

Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.

21 January 2018

1 reference

Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-lactamase fusion protein

21 January 2018

1 reference

Efficient cancer therapy with a nanobody-based conjugate

21 January 2018

1 reference

Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)

21 January 2018

1 reference

Design and synthesis of a beta-lactamase activated 5-fluorouracil prodrug.

21 January 2018

1 reference

Developing bifunctional beta-lactamase molecules with built-in target-recognizing module for prodrug therapy: identification of Enterobacter Cloacae P99 cephalosporinase loops suitable for randomization and phage-display selection

21 January 2018

1 reference

Essential roles of zinc ligation and enzyme dimerization for catalysis in the aminoacylase-1/M20 family

21 January 2018

1 reference

Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).

21 January 2018

1 reference

In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein

21 January 2018

1 reference

Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein

21 January 2018

1 reference

Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy.

21 January 2018

1 reference

Production of recombinant protein in Pichia pastoris by fermentation.

21 January 2018

1 reference

From laboratory to Phase I/II cancer trials with recombinant biotherapeutics

21 January 2018

1 reference

A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.

21 January 2018

1 reference

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids

21 January 2018

1 reference

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

21 January 2018

1 reference

Antibody-directed enzyme prodrug therapy for cancer: its theoretical basis and application

21 January 2018

1 reference

PEGylation of therapeutic proteins

21 January 2018

1 reference

Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics

21 January 2018

1 reference

A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics

21 January 2018

1 reference

T cell epitope: friend or foe? Immunogenicity of biologics in context

21 January 2018

1 reference

Immunomics: discovering new targets for vaccines and therapeutics

21 January 2018

1 reference

Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics

21 January 2018

1 reference

A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy

21 January 2018

1 reference

A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.

21 January 2018

1 reference

Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).

21 January 2018

1 reference

In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein

21 January 2018

1 reference

Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer

21 January 2018

1 reference

Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C.

21 January 2018

1 reference

Selective chemical catalysis by an antibody

21 January 2018

1 reference

21 January 2018

1 reference

Catalytic antibodies: hapten design strategies and screening methods

21 January 2018

1 reference

IgG antibodies with peroxidase-like activity from the sera of healthy Wistar rats

21 January 2018

1 reference

Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde.

21 January 2018

1 reference

Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.

21 January 2018

1 reference

In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy

21 January 2018

1 reference

Catalytic activity of certain antibodies as a potential tool for drug synthesis and for directed prodrug therapies

21 January 2018

1 reference

Human catalytic antibody Se-scFv-B3 with high glutathione peroxidase activity

21 January 2018

1 reference

Improving GPX activity of selenium-containing human single-chain Fv antibody by site-directed mutation based on the structural analysis

21 January 2018

1 reference

The antibody-catalyzed water oxidation pathway--a new chemical arm to immune defense?

21 January 2018

1 reference

Catalytic methods for the destruction of chemical warfare agents under ambient conditions

21 January 2018

1 reference

Antibody-catalyzed anaerobic destruction of methamphetamine

21 January 2018

1 reference

Identification and characterization of single chain anti-cocaine catalytic antibodies

21 January 2018

1 reference

Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain

21 January 2018

1 reference

Mutational and inhibitory analysis of a catalytic antibody. Implication for drug discovery

21 January 2018

1 reference

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue

21 January 2018

1 reference

Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance.

21 January 2018

1 reference

Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies

21 January 2018

1 reference

Enzyme-catalyzed activation of anticancer prodrugs

21 January 2018

1 reference

Prodrugs: design and clinical applications.

21 January 2018

1 reference

Mammalian antimicrobial proteins and peptides: overview on the RNase A superfamily members involved in innate host defence

21 January 2018

1 reference

From housekeeper to microsurgeon: the diagnostic and therapeutic potential of ribonucleases

21 January 2018

1 reference

Cytotoxicity of RNases is increased by cationization and counteracted by K(Ca) channels

21 January 2018

1 reference

Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein

21 January 2018

1 reference

Design of cytotoxic ribonucleases by cationization to enhance intracellular protein delivery

21 January 2018

1 reference

RNase-induced apoptosis: fate of calcium-activated potassium channels

21 January 2018

1 reference

The cytotoxic ribonuclease onconase targets RNA interference (siRNA).

21 January 2018

1 reference

Antineoplastic ribonucleases selectively kill thyroid carcinoma cells via caspase-mediated induction of apoptosis.

21 January 2018

1 reference

Degradation of double-stranded RNA by human pancreatic ribonuclease: crucial role of noncatalytic basic amino acid residues

21 January 2018

1 reference

Noncatalytic assembly of ribonuclease III with double-stranded RNA.

21 January 2018

1 reference

Alpha-sarcin catalytic activity is not required for cytotoxicity

21 January 2018

1 reference

Immunotoxin treatment of cancer

21 January 2018

1 reference

Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies

21 January 2018

1 reference

Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.

21 January 2018

1 reference

Clinical experience with denileukin diftitox (ONTAK).

21 January 2018

1 reference

Ribosome-inactivating proteins: progress and problems.

21 January 2018

1 reference

Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies

21 January 2018

1 reference

RNase A ribonucleases and host defense: an evolving story

21 January 2018

1 reference

Ribonuclease inhibitor: structure and function

21 January 2018

1 reference

Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity

21 January 2018

1 reference

Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent

21 January 2018

1 reference

Ribonucleases expressed by human pancreatic adenocarcinoma cell lines

21 January 2018

1 reference

Natural and engineered cytotoxic ribonucleases: therapeutic potential

21 January 2018

1 reference

Cloning and cytotoxicity of a human pancreatic RNase immunofusion

21 January 2018

1 reference

Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.

21 January 2018

1 reference

A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.

21 January 2018

1 reference

A novel human antitumor dimeric immunoRNase.

21 January 2018

1 reference

Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies

21 January 2018

1 reference

New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo

21 January 2018

1 reference

Human antibody RNase fusion protein targeting CD30+ lymphomas.

21 January 2018

1 reference

Silencing an inhibitor unleashes a cytotoxic enzyme

21 January 2018

1 reference

A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity.

21 January 2018

1 reference

Endowing human pancreatic ribonuclease with toxicity for cancer cells

21 January 2018

1 reference

Angiogenin: a review of the pathophysiology and potential clinical applications

21 January 2018

1 reference

Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.

21 January 2018

1 reference

The C-terminal region of human angiogenin has a dual role in enzymatic activity

21 January 2018

1 reference

Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme.

21 January 2018

1 reference

Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers.

21 January 2018

1 reference

A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells.

21 January 2018

1 reference

Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells.

21 January 2018

1 reference

Humanization of immunotoxins

21 January 2018

1 reference

Cancer chemotherapy--ribonucleases to the rescue

21 January 2018

1 reference

Ribonucleases as potential modalities in anticancer therapy

21 January 2018

1 reference

Binase and other microbial RNases as potential anticancer agents

21 January 2018

1 reference

Homology between prokaryotic and eukaryotic ribonucleases

21 January 2018

1 reference

Fungal ribotoxins: molecular dissection of a family of natural killers

21 January 2018

1 reference

Protein-protein recognition: crystal structural analysis of a barnase-barstar complex at 2.0-A resolution

21 January 2018

1 reference

Translocation mediated by domain II of Pseudomonas exotoxin A: transport of barnase into the cytosol

21 January 2018

1 reference

Studies on the activity of barnase toxins in vitro and in vivo

21 January 2018

1 reference

Barnase as a new therapeutic agent triggering apoptosis in human cancer cells

21 January 2018

1 reference

21 January 2018

1 reference

Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family

21 January 2018

1 reference

Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase

21 January 2018

1 reference

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma

21 January 2018

1 reference

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents

21 January 2018

1 reference

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics

21 January 2018

1 reference

Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin

21 January 2018

1 reference

Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein

21 January 2018

1 reference

Comprehensive comparison of the cytotoxic activities of onconase and bovine seminal ribonuclease

21 January 2018

1 reference

Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin

21 January 2018

1 reference

Structure and stability of the non-covalent swapped dimer of bovine seminal ribonuclease: an enzyme tailored to evade ribonuclease protein inhibitor.

21 January 2018

1 reference

The buried diversity of bovine seminal ribonuclease: shape and cytotoxicity of the swapped non-covalent form of the enzyme

21 January 2018

1 reference

A role for the intersubunit disulfides of seminal RNase in the mechanism of its antitumor action

21 January 2018

1 reference

On the track of antitumour ribonucleases

21 January 2018

1 reference

Comparison of the structural and functional properties of RNase A and BS-RNase: a stepwise mutagenesis approach.

21 January 2018

1 reference

Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins

21 January 2018

1 reference

Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy

21 January 2018

1 reference

Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions.

21 January 2018

1 reference

Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells.

21 January 2018

1 reference

DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis

21 January 2018

1 reference

Granule-mediated killing: pathways for granzyme B-initiated apoptosis.

21 January 2018

1 reference

Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax.

21 January 2018

1 reference

Efficient Nuclear Targeting of Granzyme B and the Nuclear Consequences of Apoptosis Induced by Granzyme B and Perforin Are Caspase-dependent, but Cell Death Is Caspase-independent

21 January 2018

1 reference

Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition

21 January 2018

1 reference

Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells

21 January 2018

1 reference

Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.

21 January 2018

1 reference

Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity

21 January 2018

1 reference

A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors

21 January 2018

1 reference

A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma

21 January 2018

1 reference

Structural mechanism for inactivation and activation of CAD/DFF40 in the apoptotic pathway

21 January 2018

1 reference

Unique recombinant human ribonuclease and inhibition of Kaposi's sarcoma cell growth

21 January 2018

1 reference

Growth inhibition of mammalian cells by eosinophil cationic protein

21 January 2018

1 reference

Biochemistry: designer enzymes

21 January 2018

1 reference

Cytotoxicity of Bovine Seminal Ribonuclease: Monomer versus Dimer†

21 January 2018

1 reference

The structural and sequence homology of a family of microbial ribonucleases

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.10.90

1 reference

24 August 2017

1 reference